The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
The mega-trend Bioconvergence represents a new frontier of scientific collaboration due to the significant advancement in digital infrastructure and tools. Scientific discovery to real world implementation remains a lengthy and costly endeavor within healthcare. However, digital technologies enable accelerated scientific understanding in all aspects of therapeutic development. At Merck KGaA, we are bringing together the right technologies, knowledge, and partners across our businesses in Life Science, Healthcare and Electronics to accelerate the speed and impact of scientific discovery. In order to transform traditional drug discovery and development, we are currently building an AI and automation ecosystem for drug discovery as well as implementation of key technologies that increase the clinical phase probability and rate of success.
Speaker(s):
Laura
Matz,
Chief Science & Technology Officer,
Merck KGaA
Credits
Credits: None available.
You must be logged in and own this session in order to
post comments.